Organogenesis Holdings Inc. · Purchase · Class A Common Stock

What does this filing report?

An SEC Form 4 filing for Organogenesis Holdings Inc. records a purchase involving Class A Common Stock on May 14, 2025. The reported quantity was 251,001. The filing date is November 3, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.10, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.9725 to $3.00, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $3.505, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F4

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.59, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F5

The reporting person's sale of an aggregate of 22,776 shares of the issuer's Class A common stock on June 9, 2025 and June 10, 2025 reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, with the reporting person's purchase of 22,776 shares of the issuer's Class A common stock on May 15, 2025. The reporting person has paid to the issuer an amount equal to $13,285.24, representing the full amount of the profit realized in connection with the short-swing transaction ($12,971.78) plus interest at the rate of 6% per annum through the date of payment ($313.46).

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.